Cortical gray matter atrophy in healthy aging cannot be explained by undetected incipient cognitive disorders: a comment on Burgmans et al. (2009)
- PMID: 20230119
- PMCID: PMC3068612
- DOI: 10.1037/a0018827
Cortical gray matter atrophy in healthy aging cannot be explained by undetected incipient cognitive disorders: a comment on Burgmans et al. (2009)
Abstract
Burgmans, van Boxtel, Vuurman, et al. (2009) published an interesting study titled "The Prevalence of Cortical Gray Matter Atrophy May Be Overestimated in the Healthy Aging Brain" on how subclinical cognitive disorders may affect correlations between age and cortical volume. Correlations between cortical gray matter volume and age were found in 30 elderly with cognitive decline after 6 years, but not in 28 elderly without cognitive decline. This study is important, and demonstrates that preclinical cognitive disorders may affect cortical brain volumes before being detectable by neuropsychological tests. However, we are not convinced by the conclusions: "... gray matter atrophy... is to a lesser extent associated with the healthy aging process, but more likely with brain processes underlying significant cognitive decline" (p. 547) and "... cortical gray matter atrophy in the aging brain may be overestimated in a large number of studies on healthy aging" (p. 547). We analyzed the cross-sectional MR data (n = 1,037) as well as longitudinal data from a sample of very well-screened elderly followed by cognitive testing for 2 years. In the cross-sectional data, the correlations between age and brain volumes were generally not much reduced when the upper age limit was lowered. This would not be expected if age-related incipient cognitive disorders caused the correlations given that the incidence of cognitive decline increased with age. Longitudinally, 1-year atrophy was identified in all tested regions. It is likely that cortical brain atrophy is manifested in cognitively normal elderly without subclinical cognitive disorders.
Copyright 2010 APA, all rights reserved
Conflict of interest statement
Anders M. Dale is a founder and holds equity in CorTechs Labs., Inc., and also serves on the scientific advisory board. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies.
Comment on
-
Prefrontal cortex atrophy predicts dementia over a six-year period.Neurobiol Aging. 2009 Sep;30(9):1413-9. doi: 10.1016/j.neurobiolaging.2007.11.028. Epub 2008 Feb 6. Neurobiol Aging. 2009. PMID: 18258339
References
-
- Allen JS, Bruss J, Brown CK, Damasio H. Normal neuroanatomical variation due to age: The major lobes and a parcellation of the temporal region. Neurobiology of Aging. 2005;26:1245–1260. discussion, 1279–1282. - PubMed
-
- Burgmans S, van Boxtel MP, Smeets F, Vuurman EF, Gronenschild EH, Verhey FR, Uylings HB, Jolles J. Prefrontal cortex atrophy predicts dementia over a six-year period. Neurobiology of Aging. 2009;30:1413–1419. - PubMed
-
- Burgmans S, van Boxtel MP, Vuurman EF, Smeets F, Gronenschild EH, Uylings HB, Jolles J. The prevalence of cortical gray matter atrophy may be overestimated in the healthy aging brain. Neuropsychology. 2009;23:541–550. - PubMed
-
- Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and surface reconstruction. NeuroImage. 1999;9:179–194. - PubMed
-
- Dale AM, Sereno MI. Improved localization of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: A linear approach. Journal of Cognitive Neuroscience. 1993;5:162–176. - PubMed
Publication types
MeSH terms
Grants and funding
- U24 RR021382/RR/NCRR NIH HHS/United States
- P50 AG05681/AG/NIA NIH HHS/United States
- R01-RR13609/RR/NCRR NIH HHS/United States
- R01EB006758/EB/NIBIB NIH HHS/United States
- R01 NS039581/NS/NINDS NIH HHS/United States
- R01 NS052585-01/NS/NINDS NIH HHS/United States
- R01 EB001550/EB/NIBIB NIH HHS/United States
- R01 NS052585/NS/NINDS NIH HHS/United States
- R01 RR16594-01A1/RR/NCRR NIH HHS/United States
- R01 RR016594/RR/NCRR NIH HHS/United States
- R01 RR013609/RR/NCRR NIH HHS/United States
- R01-NS39581/NS/NINDS NIH HHS/United States
- R01 EB006758/EB/NIBIB NIH HHS/United States
- R37-AG11230/AG/NIA NIH HHS/United States
- P41-RR14075/RR/NCRR NIH HHS/United States
- P20 MH071616/MH/NIMH NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- U19 AG010483/AG/NIA NIH HHS/United States
- U54 EB005149/EB/NIBIB NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P01 AG03991/AG/NIA NIH HHS/United States
- P41 RR014075/RR/NCRR NIH HHS/United States
- R37 AG011230/AG/NIA NIH HHS/United States
- RR 16594/RR/NCRR NIH HHS/United States
- RR14075/RR/NCRR NIH HHS/United States
- P50 MH071616/MH/NIMH NIH HHS/United States
